NeuroSense Therapeutics Ltd. Ordinary Shares — Rendiconto Finanziario Trimestrale (NASDAQ:NRSN) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 23.77 M
Employee 15
Founded 2017
CEO N/A
Website www.neurosense-tx.com
Headquarter Israel
FIGI UNKNOWN
Industry Technology

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

23.77 M Capitalizzazione di mercato

Notizie

Roth/MKM avvia copertura su NeuroSense con buy per potenziale farmaco SLA

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential

Il titolo di Neurosense Therapeutics sale dopo aver ottenuto un brevetto australiano per PrimeC

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

Il titolo di Neurosense sale mentre il farmaco per l’Alzheimer mostra un profilo di sicurezza favorevole

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)